Type-B monoamine oxidase inhibitors in neurological diseases:clinical applications based on preclinical findings  

作　　者：Marika Alborghetti Edoardo Bianchini Lanfranco De Carolis Silvia Galli Francesco E.Pontieri Domiziana Rinaldi 

机构地区：[1]Neurology Unit,NESMOS Department,Faculty of Medicine&Psychology,Sapienza-University of Rome,Sant’Andrea University Hospital,Rome,Italy [2]Department of Clinical and Behavioral Neurology,IRCCS-Fondazione Santa Lucia,Rome,Italy

出　　处：《Neural Regeneration Research》2024年第1期16-21,共6页中国神经再生研究（英文版）

摘　　要：Type-B monoamine oxidase inhibitors,encompassing selegiline,rasagiline,and safinamide,are available to treat Parkinson's disease.These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease.There is also evidence suppo rting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson's disease,such as mood deflection,cognitive impairment,sleep disturbances,and fatigue.Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson's disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors,particularly glial cell line-derived neurotrophic factor,which suppo rt dopaminergic neurons.Besides,safinamide may interfere with neurodegenerative mechanisms,countera cting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity.Due to the dual mechanism of action,the new generation of type-B monoamine oxidase inhibitors,including safinamide,is gaining interest in other neurological pathologies,and many supporting preclinical studies are now available.The potential fields of application concern epilepsy,Duchenne muscular dystrophy,multiple scle rosis,and above all,ischemic brain injury.The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline,rasagiline,and safinamide in Parkinson's disease and beyond,focusing on possible future therapeutic applications.

关 键 词：glial cell line-derived neurotrophic factor(GDNF) GLUTAMATE neurological disorders NEUROPROTECTION Parkinson's disease preclinical studies RASAGILINE SAFINAMIDE SELEGILINE type-B monoamine oxidase(MAO_(B))inhibitors 

分 类 号：R741.05[医药卫生—神经病学与精神病学]